Aclaris Therapeutics (ACRS) Operating Expenses (2014 - 2026)

Aclaris Therapeutics' Operating Expenses history runs 13 years deep, the most recent figure standing at $24.2 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 23.79% year-over-year to $24.2 million in Q1 2026; TTM through Mar 2026 was $88.8 million, a 44.07% decrease from a year earlier, with the FY2025 full-year figure at $84.2 million, down 47.59% from the prior year.
• Operating Expenses advanced to $24.2 million in Q1 2026 per ACRS's latest filing, from $24.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $108.9 million in Q4 2024 and bottomed at $14.8 million in Q3 2024.
• The 5-year median for Operating Expenses is $22.5 million (2022), against an average of $30.4 million.
• Across the five-year window, Operating Expenses jumped 403.71% in 2024 and sank 77.93% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $36.8 million in 2022, then plunged by 41.31% to $21.6 million in 2023, then soared by 403.71% to $108.9 million in 2024, then sank by 77.93% to $24.0 million in 2025, then rose by 0.66% to $24.2 million in 2026.
• Per Business Quant, the three latest ACRS Operating Expenses figures stand at $24.2 million (Q1 2026), $24.0 million (Q4 2025), and $20.4 million (Q3 2025).